13 results on '"von Loeffelholz, Christian"'
Search Results
2. Endoplasmic reticulum stress and the unfolded protein response in skeletal muscle of subjects suffering from peritoneal sepsis.
- Author
-
Metzing, Uta Barbara, von Loeffelholz, Christian, Steidl, Ricardo, Romeike, Bernd, Winkler, René, Rauchfuß, Falk, Settmacher, Utz, Stoppe, Christian, Coldewey, Sina M., Weinmann, Claudia, Weickert, Martin O., Claus, Ralf A., Birkenfeld, Andreas L., Kosan, Christian, and Horn, Paul
- Subjects
- *
UNFOLDED protein response , *SKELETAL muscle , *ENDOPLASMIC reticulum , *HEAT shock proteins , *SEPSIS , *LABORATORY mice - Abstract
We provide a descriptive characterization of the unfolded protein response (UPR) in skeletal muscle of human patients with peritoneal sepsis and a sepsis model of C57BL/6J mice. Patients undergoing open surgery were included in a cross-sectional study and blood and skeletal muscle samples were taken. Key markers of the UPR and cluster of differentiation 68 (CD68) as surrogate of inflammatory injury were evaluated by real-time PCR and histochemical staining. CD68 mRNA increased with sepsis in skeletal muscle of patients and animals (p < 0.05). Mainly the inositol-requiring enzyme 1α branch of the UPR was upregulated as shown by elevated X-box binding-protein 1 (XBP1u) and its spliced isoform (XBP1s) mRNA (p < 0.05, respectively). Increased expression of Gadd34 indicated activation of PRKR-Like Endoplasmic Reticulum Kinase (PERK) branch of the UPR, and was only observed in mice (p < 0.001) but not human study subjects. Selected cell death signals were upregulated in human and murine muscle, demonstrated by increased bcl-2 associated X protein mRNA and TUNEL staining (p < 0.05). In conclusion we provide a first characterization of the UPR in skeletal muscle in human sepsis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Association between high dose catecholamine support and liver dysfunction following cardiac surgery.
- Author
-
Sommerfeld, Oliver, von Loeffelholz, Christian, Diab, Mahmoud, Kiessling, Stefan, Doenst, Torsten, Bauer, Michael, and Sponholz, Christoph
- Subjects
- *
CARDIAC surgery , *FATTY liver , *CARDIOPULMONARY bypass , *VENTRICULAR ejection fraction , *INTENSIVE care units , *ELECTIVE surgery - Abstract
Background: Cardiac surgery using cardiopulmonary bypass is a well-established procedure. However, up to 20% to 30% of patients require high dose vasopressor or inotropic support following surgery, enhancing the risk of organ dysfunction and impacting mortality. Nonalcoholic fatty liver disease (NAFLD) is a frequent finding in these patients and may be involved in the pathophysiology of vasoplegia and cardiac failure.Methods: Retrospective analysis of 463 patients undergoing elective cardiac surgery in 2014 at our institution. NAFLD was defined using the NAFLD fibrosis score and the vasoactive-inotropy score was used to determine postoperative vasopressor and inotropic dependency.Results: Patients with NAFLD more often presented with high vasopressor or inotropic support compared to patients without NAFLD, resulting in significant differences after 6 hours (n = 20 [27.0%] of 74 patients), 12 hours (n = 20 [27.0%] of 74 patients), and on the first postoperative day (n = 12 [16.4%] of 73 patients) of intensive care unit (ICU) treatment. Multivariate analysis revealed time of catecholamine application (P = .001), preoperative left ventricular ejection fraction (P = .001), type of surgery (P = .001), model of endstage liver disease on hospital admission (P = .002), pre-existing pulmonary hypertension (P = .004) and NAFLD-time interaction (P = .05) as independent predictors of high vasopressor and inotropic support. Patients with NAFLD had higher degrees of extrahepatic organ dysfunction, were more dependent on hemodialysis, spent more days in the ICU and within the hospital. Patients with NAFLD and high catecholamine support had the highest mortality rates among the study population.Conclusions: NAFLD is a common finding in elective cardiac surgery patients. Anesthesiologists and intensivists should be sensitive for the specific risk profile of this population. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
4. ANGPTL8 (Betatrophin) is Expressed in Visceral Adipose Tissue and Relates to Human Hepatic Steatosis in Two Independent Clinical Collectives.
- Author
-
von Loeffelholz, Christian, Pfeiffer, Andreas F. H., Lock, Johan F., Lieske, Steffi, Döcke, Stephanie, Murahovschi, Veronica, Kriebel, Jennifer, de las Heras Gala, Tonia, Grallert, Harald, Rudovich, Natalia, Stockmann, Martin, Spranger, Joachim, Jahreis, Gerhard, Bornstein, Stefan R., Lau, George, Aimin Xu, Schulz-Menger, Jeanette, Exner, Louisa, Haufe, Sven, and Jordan, Jens
- Subjects
- *
ANGIOPOIETIN-like proteins , *FATTY degeneration , *ADIPOSE tissues , *PROTEIN expression , *DIETARY supplements , *STATISTICAL correlation - Abstract
Angiopoietin-like protein 8 (ANGPTL8)/betatrophin expression in visceral adipose tissue and associations with circulating fatty acid profile have not yet been investigated. Forty subjects were included in a cross-sectional study, 57 in a dietary weight reduction intervention. Circulating Angiopoietin-like protein 8/betatrophin was measured in all subjects. Liver and adipose tissue were sampled and plasma fatty acids and tissue Angiopoietin-like protein 8/betatrophin expression were evaluated in the cross-sectional study. In the intervention study oral glucose testing and liver magnetic resonance scanning at baseline and after 6 months were performed. Angiopoietin-like protein 8/betatrophin mRNA was increased in visceral compared to subcutaneous adipose tissue (p < 0.001). Circulating ANGPTL8/betatrophin correlated with liver steatosis (r = 0.42, p = 0.047), triacylglycerols (r = 0.34, p = 0.046), saturated (r = 0.43, p = 0.022), monounsaturated (r = 0.51, p = 0.007), and polyunsaturated fatty acids (r = - 0.53, p = 0.004). In the intervention study, baseline Angiopoietin-like protein 8/betatrophin correlated with age (r = 0.32, p = 0.010) and triacylglycerols (r = 0.30, p = 0.02) and was increased with hepatic steatosis (p = 0.033). Weight loss reduced liver fat by 45% and circulating Angiopoietin-like protein 8/betatrophin by 11% (288 ± 17 vs. 258 ± 17 pg/ml; p = 0.015). Angiopoietin-like protein 8/betatrophin is related to liver steatosis, while visceral adipose tissue represents an additional site of expression in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Modulation of insulin degrading enzyme activity and liver cell proliferation.
- Author
-
Pivovarova, Olga, von Loeffelholz, Christian, Ilkavets, Iryna, Sticht, Carsten, Zhuk, Sergei, Murahovschi, Veronica, Lukowski, Sonja, Döcke, Stephanie, Kriebel, Jennifer, de las Heras Gala, Tonia, Malashicheva, Anna, Kostareva, Anna, Lock, Johan F, Stockmann, Martin, Grallert, Harald, Gretz, Norbert, Dooley, Steven, Pfeiffer, Andreas FH, and Rudovich, Natalia
- Published
- 2015
- Full Text
- View/download PDF
6. Nonalcoholic Steatohepatits and Liver Steatosis Modify Partial Hepatectomy Recovery.
- Author
-
Hoppe, Steffi, von Loeffelholz, Christian, Lock, Johan F., Doecke, Stephanie, Sinn, Bruno V., Rieger, Anja, Malinowski, Maciej, Pfeiffer, Andreas F. H., Neuhaus, Peter, and Stockmann, Martin
- Subjects
- *
FATTY degeneration , *HEPATECTOMY , *FATTY liver , *LIVER regeneration , *BREATH tests , *LIVER cancer , *PILOT projects - Abstract
Background: The impact of nonalcoholic fatty liver disease (NAFLD) comprising simple steatosis (NAFL) and steatohepatitis (NASH) on liver recovery after partial hepatectomy has not been evaluated. This pilot study investigated whether there is an effect of proven NAFLD on liver recovery. Methods: Thirty-one patients elected for partial hepatectomy were characterized and included into a prospective study. Liver samples were staged according to the NAFLD activity score. Liver function was measured by using the LiMAx method on postoperative days (POD) 1, 3, 5, and 10. Results: Nineteen patients were identified to suffer from NAFLD (NAFL, n = 11; NASH, n = 8). In NAFL, preoperative liver function ( p = .48) and hepatic recovery on POD 1, 3, and 5 was comparable to controls ( p > .05, respectively), while it was impaired on POD 10 ( p = .022). NASH patients had preoperative enzymatic function comparable to controls ( p = .10), but there was a trend to reduced levels on POD 1 ( p = .082) and 5 ( p = .062), which became significant on POD 10 ( p = .003). Conclusion: This study suggests that NAFLD impairs functional recovery assessed by LiMAx after partial hepatectomy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies.
- Author
-
von Loeffelholz, Christian, Coldewey, Sina M., and Birkenfeld, Andreas L.
- Subjects
- *
NON-alcoholic fatty liver disease , *SKELETAL muscle , *LIPID synthesis , *ADENOSINE monophosphate , *ADIPOSE tissues , *HUMAN experimentation , *PATHOGENESIS , *G proteins - Abstract
5′AMP-activated protein kinase (AMPK) is known as metabolic sensor in mammalian cells that becomes activated by an increasing adenosine monophosphate (AMP)/adenosine triphosphate (ATP) ratio. The heterotrimeric AMPK protein comprises three subunits, each of which has multiple phosphorylation sites, playing an important role in the regulation of essential molecular pathways. By phosphorylation of downstream proteins and modulation of gene transcription AMPK functions as a master switch of energy homeostasis in tissues with high metabolic turnover, such as the liver, skeletal muscle, and adipose tissue. Regulation of AMPK under conditions of chronic caloric oversupply emerged as substantial research target to get deeper insight into the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Evidence supporting the role of AMPK in NAFLD is mainly derived from preclinical cell culture and animal studies. Dysbalanced de novo lipogenesis has been identified as one of the key processes in NAFLD pathogenesis. Thus, the scope of this review is to provide an integrative overview of evidence, in particular from clinical studies and human samples, on the role of AMPK in the regulation of primarily de novo lipogenesis in human NAFLD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Predictive Value of Serial Model of End-Stage Liver Disease Score Determination in Patients with Postcardiotomy Extracorporeal Membrane Oxygenation.
- Author
-
Sommerfeld, Oliver, Neumann, Caroline, Pfeifer, Marcel-Dominic, Faerber, Gloria, Kirov, Hristo, von Loeffelholz, Christian, Doenst, Torsten, and Sponholz, Christoph
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *LIVER diseases , *MULTIPLE organ failure , *HOSPITAL mortality , *CARDIAC output - Abstract
(1) Background: The use of extracorporeal membrane oxygenation (ECMO) in low cardiac output states after cardiac surgery may aid in patient recovery. However, in some patients, the clinical state may worsen, resulting in multiple organ failure and high mortality rates. In these circumstances, calculating a model of end-stage liver disease (MELD) score was shown to determine organ dysfunction and predicting mortality. (2) Methods: We evaluated whether serial MELD score determination increases mortality prediction in patients with postcardiotomy ECMO support. (3) Results: Statistically, a cutoff of a 2.5 MELD score increase within 48 h of ECMO initiation revealed an AUC of 0.722. Further, we found a significant association between hospital mortality and 48 h MELD increase (HR: 2.5, 95% CI: 1.33–4.75, p = 0.005) after adjustment for possible confounders. (4) Conclusions: Therefore, serial MELD score determinations on alternate days may be superior to single measurements in this special patient cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Deletion of the diabetes candidate gene Slc16a13 in mice attenuates diet-induced ectopic lipid accumulation and insulin resistance.
- Author
-
Schumann, Tina, König, Jörg, von Loeffelholz, Christian, Vatner, Daniel F., Zhang, Dongyan, Perry, Rachel J., Bernier, Michel, Chami, Jason, Henke, Christine, Kurzbach, Anica, El-Agroudy, Nermeen N., Willmes, Diana M., Pesta, Dominik, de Cabo, Rafael, O´Sullivan, John F., Simon, Eric, Shulman, Gerald I., Hamilton, Bradford S., and Birkenfeld, Andreas L.
- Subjects
- *
DIABETES , *LIPIDS , *INSULIN resistance , *CELL membranes , *FATTY liver - Abstract
Genome-wide association studies have identified SLC16A13 as a novel susceptibility gene for type 2 diabetes. The SLC16A13 gene encodes SLC16A13/MCT13, a member of the solute carrier 16 family of monocarboxylate transporters. Despite its potential importance to diabetes development, the physiological function of SLC16A13 is unknown. Here, we validate Slc16a13 as a lactate transporter expressed at the plasma membrane and report on the effect of Slc16a13 deletion in a mouse model. We show that Slc16a13 increases mitochondrial respiration in the liver, leading to reduced hepatic lipid accumulation and increased hepatic insulin sensitivity in high-fat diet fed Slc16a13 knockout mice. We propose a mechanism for improved hepatic insulin sensitivity in the context of Slc16a13 deficiency in which reduced intrahepatocellular lactate availability drives increased AMPK activation and increased mitochondrial respiration, while reducing hepatic lipid content. Slc16a13 deficiency thereby attenuates hepatic diacylglycerol-PKCε mediated insulin resistance in obese mice. Together, these data suggest that SLC16A13 is a potential target for the treatment of type 2 diabetes and non-alcoholic fatty liver disease. Schumann et al. demonstrate that the loss of a lactate transporter Slc16a13 increases mitochondrial respiration in the liver, which reduces hepatic lipid accumulation while increasing hepatic insulin sensitivity in mice fed a high-fat diet. This study suggests SLC16A13 as a potential target for the treatment of type 2 diabetes and non-alcoholic fatty liver disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Publisher Correction: Deletion of the diabetes candidate gene Slc16a13 in mice attenuates diet-induced ectopic lipid accumulation and insulin resistance.
- Author
-
Schumann, Tina, König, Jörg, von Loeffelholz, Christian, Vatner, Daniel F., Zhang, Dongyan, Perry, Rachel J., Bernier, Michel, Chami, Jason, Henke, Christine, Kurzbach, Anica, El-Agroudy, Nermeen N., Willmes, Diana M., Pesta, Dominik, de Cabo, Rafael, O´Sullivan, John F., Simon, Eric, Shulman, Gerald I., Hamilton, Bradford S., and Birkenfeld, Andreas L.
- Subjects
- *
INSULIN resistance , *GENETICS of diabetes , *ECTOPIC tissue - Published
- 2021
- Full Text
- View/download PDF
11. Meeting nutritional targets of critically ill patients by combined enteral and parenteral nutrition: review and rationale for the EFFORTcombo trial.
- Author
-
Hill, Aileen, Heyland, Daren K., Elke, Gunnar, Schaller, Stefan J., Stocker, Reto, Haberthür, Christoph, von Loeffelholz, Christian, Suchner, Ulrich, Puthucheary, Zudin A., Bear, Danielle E., Ney, Julia, Clasen, Kai C., Meybohm, Patrick, Lindau, Simone, Laurentius, Thea, and Stoppe, Christian
- Subjects
- *
MALNUTRITION , *CRITICALLY ill , *DIET therapy , *ENTERAL feeding , *INTENSIVE care units , *HEALTH outcome assessment , *PARENTERAL feeding , *PATIENTS , *DIETARY proteins , *ENERGY density , *NUTRITIONAL status - Abstract
While medical nutrition therapy is an essential part of the care for critically ill patients, uncertainty exists about the right form, dosage, timing and route in relation to the phases of critical illness. As enteral nutrition (EN) is often withheld or interrupted during the intensive care unit (ICU) stay, combined EN and parenteral nutrition (PN) may represent an effective and safe option to achieve energy and protein goals as recommended by international guidelines. We hypothesise that critically ill patients at high nutritional risk may benefit from such a combined approach during their stay on the ICU. Therefore, we aim to test if an early combination of EN and high-protein PN (EN+PN) is effective in reaching energy and protein goals in patients at high nutritional risk, while avoiding overfeeding. This approach will be tested in the here-presented EFFORTcombo trial. Nutritionally high-risk ICU patients will be randomised to either high (≥2·2 g/kg per d) or low protein (≤1·2 g/kg per d). In the high protein group, the patients will receive EN+PN; in the low protein group, patients will be given EN alone. EN will be started in accordance with international guidelines in both groups. Efforts will be made to reach nutrition goals within 48–96 h. The efficacy of the proposed nutritional strategy will be tested as an innovative approach by functional outcomes at ICU and hospital discharge, as well as at a 6-month follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. WISP1 Is a Novel Adipokine Linked to Inflammation in Obesity.
- Author
-
Murahovschi, Veronica, Pivovarova, Olga, Ilkavets, Iryna, Dmitrieva, Renata M., Döcke, Stephanie, Keyhani-Nejad, Farnaz, Gögebakan, Özlem, Osterhoff, Martin, Kemper, Margrit, Hornemann, Silke, Markova, Mariya, Klöting, Nora, Stockmann, Martin, Weickert, Martin O., Lamounier-Zepter, Valeria, Neuhaus, Peter, Konradi, Alexandra, Dooley, Steven, von Loeffelholz, Christian, and Blüher, Matthias
- Subjects
- *
EXTRACELLULAR matrix proteins , *ADIPOGENESIS , *ADIPOKINES , *SECRETION , *INSULIN resistance , *LABORATORY mice , *OBESITY risk factors - Abstract
WISP1 (Wnt1-inducible signaling pathway protein-1, also known as CCN4) is a member of the secreted extracellular matrix-associated proteins of the CCN family and a target gene of the Wingless-type (WNT) signaling pathway. Growing evidence links the WNT signaling pathway to the regulation of adipogenesis and low-grade inflammation in obesity. We aimed to validate WISP1 as a novel adipokine. Human adipocyte differentiation was associated with increased WISP1 expression and secretion. Stimulation of human macrophages with WISP1 led to a proinflammatory response. Circulating WISP1 and WISP1 subcutaneous adipose tissue expression were regulated by weight changes in humans and mice. WISP1 expression in visceral and subcutaneous fat tissue was associated with markers of insulin resistance and inflammation in glucose-tolerant subjects. In patients with nonalcoholic fatty liver disease, we found no correlation among disease activity score, liver fat content, and WISP1 expression. Insulin regulated WISP1 expression in adipocytes in vitro but had no acute effect on WISP1 gene expression in subcutaneous fat tissue in overweight subjects who had undergone hyperinsulinemic clamp experiments. The data suggest that WISP1 may play a role in linking obesity to inflammation and insulin resistance and could be a novel therapeutic target for obesity. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. The Mammalian INDY Homolog Is Induced by CREB in a Rat Model of Type 2 Diabetes.
- Author
-
Neuschäfer-Rube, Frank, Lieske, Stefanie, Kuna, Manuela, Henkel, Janin, Perry, Rachel J., Erion, Derek M., Pesta, Dominik, Willmes, Diana M., Brachs, Sebastian, von Loeffelholz, Christian, Tolkachov, Alexander, Schupp, Michael, Pathe-Neuschäfer-Rube, Andrea, Pfeiffer, Andreas F. H., Shulman, Gerald I., Püschel, Gerhard P., and Birkenfeld, Andreas L.
- Subjects
- *
CARBOXYLATES , *LOW-calorie diet , *TYPE 2 diabetes , *DIABETES , *LABORATORY rats - Abstract
Reduced expression of the INDY (I'm not dead yet) tricarboxylate carrier increased life span in different species by mechanisms akin to caloric restriction. The mammalian INDY homolog (mIndy) gene expression seems to be regulated by hormonal and/or nutritional factors. The underlying mechanisms are still unknown. The current study revealed that mIndy expression and [14C]-citrate uptake was induced by physiological concentrations of glucagon via a cAMP- and cAMP-responsive-element-binding protein (CREB)-dependent mechanism in primary rat hepatocytes. The promoter sequence of mIndy located upstream of the most frequent transcription start site was determined by 5'-race. In silico analysis identified a CREB-binding site within this promoter fragment of mIndy. Functional relevance for the CREB-binding site was demonstrated with reporter gene constructs, which were induced by CREB activation when under the control of a fragment of wild type promoter whereas promoter activity was lost after site directed mutagenesis of the CREB-binding site. Moreover, CREB binding to this promoter element was confirmed by chromatin immunoprecipiation in rat liver. In vivo studies revealed that mIndy was induced in livers of fasted as well as HFD-streptozotocin-diabetic rats, in which CREB is constitutively activated. mIndy induction was completely prevented when CREB was depleted in these rats by antisense oligonucleotides. Together, these data suggest that mIndy is a CREB-dependent glucagon target gene, which is induced in fasting and in type 2 diabetes. Increased mINDY expression might contribute to the metabolic consequences of diabetes in the liver. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.